Protocol Ledger

NCT06787612 · Phase II · RECRUITING

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Interventional Phase II clinical trial protocol NCT06787612 sponsored by Regeneron Pharmaceuticals in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-05-28 Enrollment: 297 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06787612
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)297 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06787612
Protocol FieldVerified Registry Value
NCT IdentifierNCT06787612
Consolidated Lead SponsorRegeneron Pharmaceuticals
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment297 participants (ESTIMATED)
Registered Start Date2025-05-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06787612
Hospital Research SiteLocationSite Profile
UC San Diego Health and Moores Cancer CenterSan Diego, CAOpen Hospital Dossier ->
Cedars-Sinai Medical CenterLos Angeles, CAOpen Hospital Dossier ->
Mayo Clinic FloridaJacksonville, FLOpen Hospital Dossier ->
University of Chicago MedicineChicago, ILOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Regeneron Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI